HBsAg Seroclearance in Chronic Hepatitis B Implications for Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Young Sun | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Yoon, Eileen | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Jong, Eun Suck | - |
dc.contributor.author | Lee, Beom Jae | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.available | 2020-11-03T03:51:01Z | - |
dc.date.issued | 2011-01 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.issn | 1539-2031 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/13825 | - |
dc.description.abstract | Goals and Background The long-term clinical course, including the development of hepatocelluar carcinoma (HCC) after hepatic B surface antigen (HBsAg) seroclearance is not established. We discovered that the incidence of HCC and the risk factors for HCC in chronic hepatitis B (CHB) patients after HBsAg seroclearance. Study During 28 years, 96 CHB patients with HBsAg seroclearance were retrospectively reviewed. These patients continued to undergo HCC surveillance. The median follow-up time from initial visit was 166.5 months (range, 7 to 321 mo). Results The mean age at the initial visit and at the time of seroclearance was 39.2±10.6 years and 46.4±9.9 years, respectively. The mean age at the time of HBsAg seroclearance was significantly lower (P=0.03) in patients with spontaneous HBsAg seroclearance than patients with treatment-associated HBsAg seroclearance. During a median of 56 months (range, 7 to 238 mo) of follow-up after HBsAg seroclearance, 6 (6.5%) patients developed HCC. The mean age at the time of developing HCC was 55.8±10.3 years. On univariate analysis, the evidence of liver cirrhosis from the time of HBsAg seroclearance and age more than 45 years at the time of HBsAg seroclearance were significant risk factors for HCC development. In multivariate analysis, the evidence of liver cirrhosis at HBsAg seroclearance was the only significant risk factor for HCC development. Conclusions HCC can develop after HBsAg seroclearance in patients with known cirrhosis. Patients who achieved HBsAg seroclearance at older age (>45) may have undiagnosed cirrhosis and hence remain at risk for HCC. HCC surveillance should be carried out for both of those patient populations. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | HBsAg Seroclearance in Chronic Hepatitis B Implications for Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MCG.0b013e3181dd558c | - |
dc.identifier.scopusid | 2-s2.0-78650953491 | - |
dc.identifier.wosid | 000285290700014 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Gastroenterology, v.45, no.1, pp 64 - 68 | - |
dc.citation.title | Journal of Clinical Gastroenterology | - |
dc.citation.volume | 45 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 64 | - |
dc.citation.endPage | 68 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN HBSAG | - |
dc.subject.keywordPlus | DELAYED CLEARANCE | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | SERUM HBSAG | - |
dc.subject.keywordPlus | CARRIERS | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordPlus | GENOTYPES | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | hepatitis B virus surface antigen | - |
dc.subject.keywordAuthor | seroclearance | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.